MagnetisMM-3 Study on Relapsed Multiple Myeloma
Studying elranatamab in patients with relapsed or refractory myeloma
The MagnetisMM-3 study (NCT04649359) evaluated the efficacy and safety of elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM). The study included patients who had not received BCMA-directed therapies before. Patients were given elranatamab through injections over several weeks. The results showed that elranatamab was effective in reducing multiple myeloma and was generally well tolerated by patients. Many patients responded well to the treatment, with some even achieving complete response. The study also found that patients who switched to a different dosing schedule experienced fewer side effects. These findings support the further development of elranatamab as a potential treatment option for multiple myeloma patients.
- Immune therapies, including CAR T cells and T cell-engaging bispecific antibodies, have shown significant advancements in multiple myeloma treatment.
- Elranatamab is a specific antibody that targets BCMA and CD3 antigens.
- The study included 123 refractory patients, with a median age of 68.
- The results showed high response rates, including complete remission (35% of patients) and very good partial responses.
- The median progression-free survival (PFS) and overall survival (OS) were not reached.
- After six months, switching to twice-monthly dosing did not impact efficacy but potentially reduced side effects.
- The safety profile of elranatamab was favorable, with low rates of cytokine release syndrome (CRS) and manageable infections.
Authors:
Mohamad Mohty, Michael H. Tomasson, Bertrand Arnulf, Nizar J. Bahlis, H. Miles Prince, Ruben Niesvizky, Paula Rodríguez-Otero, Joaquin Martinez-Lopez, Guenther Koehne, Yogesh Jethava, A. Eli Gabayan, Don A. Stevens, Ajay K. Nooka, Noopur S. Raje, Shinsuke Iida, Eric Leip, Umberto Conte, Akos Gabor Czibere, Andrea Viqueira, Alexander M. Lesokhin
Clinical Trial Information: NCT04649359
Doctor Bio:
Mohamad Mohty, MD, PhD, attended the University of Montpellier, France, where he completed his medical degree. He then undertook a PhD at the University of Marseille, France, before working at the Hematology Department at Hammersmith Hospital, London, UK.
Prof. Mohty is a Professor of Hematology and Head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He also leads a translational research team (INSERM team) at the Saint-Antoine Research Center, Paris, France. Prof. Mohty is the Chairman of the Acute Leukemia Working Party and past President of the European Society for Blood and Marrow Transplantation (EBMT). He has published over 600 peer-reviewed articles internationally and lectured in more than 70 countries.
